Bristol-Myers Squibb Co.
345 Park Avenue
New York,
NY 10154
United States - Map
Phone: 212-546-4000
Fax: 212-546-4020
Web Site: http://www.bms.com
| Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; KineMed Inc.; and Asterand plc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. James M. Cornelius , 65
Chairman, Chief executive officer, Member of Management Council and Member of Exec. Committee |
$
5.96M |
$
0 | Mr. Lamberto Andreotti , 58
Pres, Chief Operating Officer, Member of Management Council, Director and Member of Management Council |
$
3.89M |
$
0 | Mr. Lewis B. Campbell , 62
Lead Independent Director, Chairman of Compensation & Management Devel. Committee, Member of Audit Committee, Member of Committee on Directors & Corp. Governance, Chairman of Textron Inc, Chief Exec. Officer of Textron Inc and Pres of Textron Inc |
$
161.00K | N/A | Mr. Jean-Marc Huet , 40
Chief Financial Officer, Exec. VP, Member of Management Council and Member of Exec. Committee |
$
2.36M |
$
0 | Dr. Elliott Sigal M.D., Ph.D., 57
Chief Scientific Officer, Exec. VP, Pres of R&D, Member of Management Council, Member of Exec. Committee and Member of Science & Technology Committee |
$
3.07M |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
Profile
